A Case of Achieving Partial Remission with the Combination of Sorafenib and Nivolumab in a Patient with Hepatocellular Carcinoma Showing Disease Progression after Nivolumab Therapy
- Author:
Sang Youn HWANG
1
;
Seon Mi LEE
;
Jung Woo IM
;
Ki Jeong JEON
;
Cheol Won CHOI
;
Kyung Su KIM
;
Wan JEON
Author Information
- Publication Type:Case Report
- Keywords: Hepatocellular carcinoma; Sorafenib; Nivolumab
- MeSH: Carcinoma, Hepatocellular; Disease Progression; Humans; Protein-Tyrosine Kinases
- From:Journal of Liver Cancer 2019;19(1):74-78
- CountryRepublic of Korea
- Language:English
- Abstract: Sorafenib is a well-known approved systemic therapeutic agent used in patients with advanced hepatocellular carcinoma (HCC). Regorafenib and nivolumab are approved as second-line therapeutic drugs in patients showing disease progression after sorafenib therapy. However, there is no established third- or fourth-line therapy in patients with progression after regorafenib or nivolumab treatment. Recently, the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICPIs) has been attempted as a first-line treatment strategy in advanced HCC patients based on the hypothesis that combination therapy may overcome resistance in ICPI monotherapy. On the basis of this suggestion, we herein describe the case of an HCC patient demonstrating macrovascular invasion, whereby partial remission was achieved via the combination of sorafenib and nivolumab following disease progression after nivolumab therapy. Further studies on the combination of TKIs and ICPIs are necessary to determine ways to manage HCC patients showing disease progression after ICPI therapy.
